https://formycon.metamove.net/blog/press-release/ 2026-08-11T21:02:58+00:00 https://formycon.metamove.net/en/blog/press-release/ 2026-08-11T21:02:58+00:00 https://formycon.metamove.net/blog/press-release/die-formycon-ag-gibt-die-berufung-von-dr-gerhard-schaefer-sowie-simon-sturge-in-ihr-advisory-board-bekannt/ 2022-02-15T13:33:43+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-kapitalerhoehung-erfolgreich-platziert/ 2022-02-15T13:38:19+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-unterzeichnet-erste-biosimilar-lizenzvereinbarung-mit-der-santo-holding-gmbh-2/ 2022-02-15T13:38:54+00:00 https://formycon.metamove.net/blog/press-release/ms-pharma-wird-kommerzialisierungspartner-fuer-fyb201-formycons-biosimilar-kandidat-fuer-lucentisr1-ranibizumab-in-der-mena-region/ 2022-02-18T08:20:14+00:00 https://formycon.metamove.net/blog/press-release/formycons-wissenschaftliche-kooperationspartner-praesentieren-fyb207-ergebnisse-auf-internationalem-keystone-symposium/ 2022-02-18T08:25:17+00:00 https://formycon.metamove.net/blog/press-release/innovativer-sars-cov-2-blocker-von-formycon-verhindert-infektion-von-zellen-vollstaendig/ 2022-02-18T08:25:41+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-bioeq-geben-start-der-phase-iii-studie-mit-fyb202-einem-biosimilar-kandidat-zu-stelarar-ustekinumab-bekannt/ 2022-02-18T08:26:11+00:00 https://formycon.metamove.net/blog/press-release/formycon-erhaelt-foerdermittel-fuer-covid-19-arzneimittelforschung-von-der-bayerischen-forschungsstiftung/ 2022-02-18T08:26:48+00:00 https://formycon.metamove.net/blog/press-release/strategischer-investor-active-ownership-gruppe-zeichnet-barkapitalerhoehung-in-hoehe-von-2575-mio-euro/ 2022-02-18T08:26:58+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-bioeq-schliessen-ersten-patienten-in-phase-iii-studie-mit-aflibercept-biosimilar-fyb203-ein/ 2022-02-18T08:27:33+00:00 https://formycon.metamove.net/blog/press-release/formycon-beginnt-antikoerperbasierte-arzneimittelentwicklung-gegen-covid-19/ 2022-02-18T08:28:23+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-neunmonatsergebnis-fuer-2019/ 2022-02-18T08:29:03+00:00 https://formycon.metamove.net/blog/press-release/bioeq-ip-ag-vergibt-exklusive-us-vermarktungsrechte-fuer-fyb201-an-coherus-biosciences-inc/ 2022-02-18T08:29:16+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-start-der-klinischen-phase-i-studie-mit-ustekinumab-biosimilar-kandidat-fyb202-bekannt/ 2022-02-18T08:29:26+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroeffentlicht-halbjahresergebnis-2019/ 2022-02-18T08:29:35+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-ordentliche-hauptversammlung-2019/ 2022-02-18T08:29:45+00:00 https://formycon.metamove.net/blog/press-release/formycon-informiert-ueber-verlauf-der-kapitalmassnahme/ 2022-02-18T08:29:54+00:00 https://formycon.metamove.net/blog/press-release/formycon-legt-zahlen-fuer-das-erste-quartal-vor/ 2022-02-18T08:30:04+00:00 https://formycon.metamove.net/blog/press-release/formycon-informiert-ueber-aktuellen-stand-der-kapitalmassnahme/ 2022-02-18T08:30:17+00:00 https://formycon.metamove.net/blog/press-release/formycon-verzeichnet-erfolgreiches-geschaeftsjahr-2018/ 2022-02-18T08:30:27+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-neuigkeiten-zum-entwicklungsportfolio-bekannt/ 2022-02-18T08:30:40+00:00 https://formycon.metamove.net/blog/press-release/strategischer-investor-m-und-h-equity-ag-zeichnet-barkapitalerhoehung-in-hoehe-von-173-millionen-euro/ 2022-02-18T08:30:51+00:00 https://formycon.metamove.net/blog/press-release/formycon-platziert-barkapitalerhoehung-in-hoehe-von-17-millionen-euro-bei-institutionellem-investor/ 2022-02-18T08:31:01+00:00 https://formycon.metamove.net/blog/press-release/formycon-informiert-ueber-entwicklungsprogramme-und-meilensteine/ 2022-02-18T08:31:13+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-neunmonatszahlen-fuer-2018/ 2022-02-18T08:31:23+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-finanzielle-und-operative-ergebnisse-fuer-das-erste-halbjahr-2018/ 2022-02-18T08:31:34+00:00 https://formycon.metamove.net/blog/press-release/formycon-beruft-entwicklungs-und-produktionsexperten-thomas-siklosi-in-das-advisory-board/ 2022-02-18T08:31:45+00:00 https://formycon.metamove.net/blog/press-release/formycon-mit-deutlichem-umsatz-und-ergebniszuwachs-im-ersten-quartal-2018-2/ 2022-02-18T08:31:57+00:00 https://formycon.metamove.net/blog/press-release/formycon-mit-erfolgreichem-geschaeftsjahr-2017-2/ 2022-02-18T08:32:07+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-bioeq-erreichen-wichtigen-meilenstein-ranibizumab-biosimilar-kandidat-fyb201-zeigt-in-phase-iii-studie-vergleichbare-wirksamkeit-zum-referenzprodukt/ 2022-02-18T08:32:17+00:00 https://formycon.metamove.net/blog/press-release/biosimilar-kandidat-fyb201-zeigt-in-phase-iii-studie-vergleichbare-wirksamkeit-zum-referenzprodukt/ 2022-02-18T08:32:29+00:00 https://formycon.metamove.net/blog/press-release/formycon-auf-platz-7-der-financial-times-liste-von-europas-1000-wachstumsstaerksten-unternehmen/ 2022-02-18T08:32:39+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-aristo-pharma-gruenden-joint-venture-fuer-die-entwicklung-von-fyb202-2/ 2022-02-18T08:32:49+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-operative-und-finanzielle-ergebnisse-fuer-drittes-quartal-2017/ 2022-02-18T08:33:03+00:00 https://formycon.metamove.net/blog/press-release/formycon-stellt-weichen-fuer-die-zukunft-und-bestaetigt-vorstaende-bis-mitte-2022/ 2022-02-18T08:33:13+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-finanzielle-und-operative-ergebnisse-fuer-erstes-halbjahr-2017/ 2022-02-18T08:33:22+00:00 https://formycon.metamove.net/blog/press-release/formycon-unterzeichnet-term-sheet-fuer-entwicklung-von-fyb202-und-fuehrt-kapitalmassnahme-durch-2/ 2022-02-18T08:33:31+00:00 https://formycon.metamove.net/blog/press-release/formycon-legt-zahlen-fuer-das-erste-quartal-2017-vor-2/ 2022-02-18T08:33:40+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-details-zu-weiterem-pipelineprodukt-bekannt-fyb202-ist-ein-biosimilar-kandidat-fuer-stelara-ustekinumab/ 2022-02-18T08:33:51+00:00 https://formycon.metamove.net/blog/press-release/formycon-mit-erfolgreichem-geschaeftsjahr-2016/ 2022-02-18T08:34:06+00:00 https://formycon.metamove.net/blog/press-release/formycon-plant-wechsel-in-neues-kmu-boersensegment-scale/ 2022-02-18T08:34:14+00:00 https://formycon.metamove.net/blog/press-release/magazin-focus-listet-formycon-wiederholt-als-wachstumschampion-2/ 2022-02-18T08:34:26+00:00 https://formycon.metamove.net/blog/press-release/formycon-mit-guter-entwicklung-in-ersten-neun-monaten-2016/ 2022-02-18T08:34:37+00:00 https://formycon.metamove.net/blog/press-release/formycon-von-stifterverband-fuer-seine-innovationskraft-ausgezeichnet/ 2022-02-18T08:34:48+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-finanzielle-und-operative-ergebnisse-fuer-das-erste-halbjahr-2016/ 2022-02-18T08:34:59+00:00 https://formycon.metamove.net/blog/press-release/formycon-erweitert-vorstand-und-beruft-pharma-top-manager-dr-stefan-glombitza-zum-chief-operating-officer/ 2022-02-18T08:35:08+00:00 https://formycon.metamove.net/blog/press-release/formycon-ceo-dr-carsten-brockmeyer-erneut-unter-die-weltweit-einflussreichsten-persoenlichkeiten-in-der-arzneimittelbranche-gewaehlt/ 2022-02-18T08:35:22+00:00 https://formycon.metamove.net/blog/press-release/formycon-legt-zahlen-fuer-das-erste-quartal-2016-vor/ 2022-02-18T08:35:33+00:00 https://formycon.metamove.net/blog/press-release/formycon-schliesst-geschaeftsjahr-2015-erfolgreich-ab/ 2022-02-18T08:35:42+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroeffentlicht-details-zu-weiterem-pipelineprodukt-fyb203-ist-ein-biosimilar-kandidat-fuer-eylea-aflibercept/ 2022-02-18T08:35:53+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-bioeq-schliessen-ersten-patienten-in-pivotale-phase-iii-studie-mit-ranibizumab-biosimilar-fyb201-ein/ 2022-02-18T08:36:04+00:00 https://formycon.metamove.net/blog/press-release/formycon-beruft-biotechexperten-professor-johannes-buchner-in-advisory-board/ 2022-02-18T08:36:15+00:00 https://formycon.metamove.net/blog/press-release/formycon-meldet-mehrere-patente-zur-pharmazeutischen-formulierung-und-verabreichung-von-intraokularen-vegf-antagonisten-an/ 2022-02-18T08:36:25+00:00 https://formycon.metamove.net/blog/press-release/formycon-legt-neunmonatszahlen-fuer-2015-vor/ 2022-02-18T08:36:39+00:00 https://formycon.metamove.net/blog/press-release/globale-strategische-partner-bioeq-und-formycon-initiieren-pivotale-klinische-phase-iii-mit-lucentis-biosimilar/ 2022-02-18T08:36:55+00:00 https://formycon.metamove.net/blog/press-release/formycon-mit-positiver-geschaeftsentwicklung-im-ersten-halbjahr-2015/ 2022-02-18T08:37:06+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-erhaelt-positiven-scientific-advice-von-der-amerikanischen-zulassungsbehoerde-fda-fuer-ihren-verpartnerten-biosimilar-produktkandidaten-fyb201/ 2022-02-18T08:37:16+00:00 https://formycon.metamove.net/blog/press-release/veroeffentlichung-der-finanzergebnisse-fuer-das-1-quartal-2015-und-anhebung-der-prognose-fuer-das-gesamtjahr-2015/ 2022-02-18T08:37:26+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-unterzeichnet-lizenzvereinbarung-fuer-das-biosimilar-fyb203/ 2022-02-18T08:37:43+00:00 https://formycon.metamove.net/blog/press-release/dr-carsten-brockmeyer-gehoert-zu-den-top-20-der-weltweit-einflussreichsten-persoenlichkeiten-auf-der-medicine-maker-power-list-2015/ 2022-02-18T08:37:53+00:00 https://formycon.metamove.net/blog/press-release/wiederbestellung-fuer-finanzvorstand-dr-nicolas-combe/ 2022-02-18T08:38:04+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-fuehrt-erfolgreiche-kapitalerhoehung-aus-genehmigtem-kapital-durch/ 2022-02-18T08:38:16+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-veroeffentlicht-vorlaeufige-konzernzahlen-fuer-das-geschaeftsjahr-2014/ 2022-02-18T08:38:53+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-besteht-erfolgreich-gmp-inspektion-und-leitet-us-fda-scientific-advice-verfahren-fuer-ihr-bereits-verpartnertes-biosimilar-produkt-fyb201-ein/ 2022-02-18T08:39:04+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-plant-start-der-pivotalen-phase-iii-studie-fuer-das-erste-biosimilar-produkt-fyb-201-fuer-das-dritte-quartal-2015/ 2022-02-18T08:39:13+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-legt-neun-monats-zahlen-fuer-2014-vor/ 2022-02-18T08:39:24+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-berichtet-ergebnisse-fuer-das-erste-halbjahr-2014/ 2022-02-18T08:39:34+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-startet-mit-der-entwicklung-des-dritten-produktes-und-bestaetigt-vorreiterrolle-bei-der-sogenannten-dritten-welle-der-biosimilars/ 2022-02-18T08:39:44+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-mit-erfolgreichem-geschaeftsjahr-2013-und-starkem-start-in-das-neue-jahr/ 2022-02-18T08:39:54+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-starker-partner-erhoeht-vermarktungspotenzial-fuer-erstes-biosimilar-entwicklungsprojekt/ 2022-02-18T08:40:06+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-beruft-us-top-pharmamanager-bernhard-hampl-in-das-advisory-board/ 2022-02-18T08:40:17+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-auslizenzierung-des-ersten-biosimilar-entwicklungsprojekts-ermoeglicht-ausbau-der-produkt-pipeline-bereits-ab-2014/ 2022-02-18T08:40:27+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-wissenschaftler-der-tu-muenchen-publizieren-neue-daten-zu-breit-wirksamen-antiviralen-sars-cov-2-medikament-fyb207/ 2022-02-18T09:25:53+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-neunmonatsergebnis-fuer-2021/ 2022-02-18T09:29:27+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-scg-cell-therapy-geben-kooperations-und-lizenzvereinbarung-fuer-formycons-covid-19-medikament-fyb207-bekannt/ 2022-02-18T09:31:15+00:00 https://formycon.metamove.net/blog/press-release/formycon-schliesst-kooperations-und-lizenzvereinbarung-fuer-covid-19-medikament-fyb207-mit-scg-cell-therapy-fuer-asiatisch-pazifische-region-ab/ 2022-02-18T09:32:47+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-bioeq-geben-annahme-des-zulassungsantrags-file-acceptance-fuer-fyb201-einen-biosimilar-kandidaten-fuer-lucentis-ranibizumab-durch-die-us-amerikanische-zulassungsbehoerde-fda-bekannt/ 2022-02-18T09:33:53+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-virtuelle-hauptversammlung-2021/ 2022-02-18T09:39:53+00:00 https://formycon.metamove.net/blog/press-release/formycons-covid-19-arzneimittel-fyb207-mit-renommiertem-pharma-trend-image-innovation-award-2021-ausgezeichnet/ 2022-02-18T09:45:21+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-den-aktuellen-stand-der-fyb207-entwicklung/ 2022-02-18T09:47:10+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-bioeq-geben-einreichung-des-zulassungsantrags-fuer-fyb201-einen-biosimilar-kandidaten-fuer-lucentisr1-ranibizumab-bei-der-us-amerikanischen-zulassungsbehoerde-fda-bekannt/ 2022-02-18T09:51:29+00:00 https://formycon.metamove.net/blog/press-release/formycon-erhaelt-foerderung-in-hoehe-von-127-millionen-euro-fuer-die-weiterentwicklung-des-covid-19-medikaments-fyb207-als-teil-der-bayerischen-therapiestrategie-zur-bekaempfung-der-covid-19-pandemie/ 2022-02-18T09:52:33+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-finanzergebnis-fuer-das-erste-quartal-2021/ 2022-02-18T09:53:48+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-bioeq-geben-einreichung-des-zulassungsantrags-fuer-fyb201-einen-biosimilar-kandidaten-fuer-lucentisr1-ranibizumab-bei-der-europaeischen-arzneimittel-agentur-ema-bekannt/ 2022-02-18T09:54:51+00:00 https://formycon.metamove.net/blog/press-release/teva-pharmaceutical-industries-ltd-wird-strategischer-partner-fuer-die-vermarktung-von-fyb201-formycons-biosimilar-kandidat-fuer-lucentisr1-ranibizumab-in-europa-kanada-israel-und-neuseeland/ 2022-02-18T10:21:19+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-abschluss-einer-exklusiven-vermarktungsvereinbarung-zwischen-bioeq-ag-und-teva-pharmaceutical-industries-ltd-fuer-europa-kanada-israel-und-neuseeland-fuer-fyb201-bekannt/ 2022-02-18T10:23:43+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-jahresabschluss-fuer-das-geschaeftsjahr-2020-bekannt/ 2022-02-18T10:25:36+00:00 https://formycon.metamove.net/blog/press-release/formycon-erhaelt-zusage-zu-vorzeitigem-massnahmenbeginn-fuer-covid-19-medikament-fyb207-im-rahmen-einer-foerderung-des-bayerischen-staatsministeriums-fuer-wirtschaft-landesentwicklung-und-energie-st/ 2022-02-18T10:28:20+00:00 https://formycon.metamove.net/blog/press-release/formycons-covid-19-medikament-fyb207-wirksamer-gegen-sars-cov-2-mutante-b-1-1-7/ 2022-02-18T10:31:12+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-leukocare-kooperieren-bei-der-entwicklung-hochwertiger-biopharmazeutika-2/ 2022-02-18T10:37:04+00:00 https://formycon.metamove.net/blog/press-release/formycon-bestaetigt-einreichungsstrategie-und-zeitschiene-fuer-lucentisr-biosimilar-kandidat-fyb201-nach-abstimmung-mit-der-fda/ 2022-02-18T10:39:52+00:00 https://formycon.metamove.net/blog/press-release/formycon-erhaelt-positiven-scientific-advice-vom-paul-ehrlich-institut-fuer-das-covid-19-medikament-fyb207-und-sichert-gmp-produktionskapazitaeten/ 2022-02-18T10:42:06+00:00 https://formycon.metamove.net/en/blog/press-release/ms-pharma-becomes-partner-for-the-commercialization-of-fyb201-formycons-biosimilar-candidate-to-lucentisr1-ranibizumab-in-the-mena-region/ 2022-02-18T11:36:33+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-scientists-from-tum-publish-new-data-on-broadly-effective-sars-cov-2-antiviral-drug-fyb207/ 2022-02-18T11:36:43+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-its-nine-month-figures-for-2021/ 2022-02-18T11:36:53+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-scg-cell-therapy-announce-collaboration-and-license-agreement-for-formycons-covid-19-drug-fyb207/ 2022-02-18T11:37:02+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-concludes-collaboration-and-license-agreement-with-scg-cell-therapy-for-its-covid-19-drug-fyb207-for-the-asia-pacific-region/ 2022-02-18T11:37:12+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-bioeq-announce-file-acceptance-for-fyb201-a-biosimilar-candidate-to-lucentis-ranibizumab-by-the-u-s-food-and-drug-administration-fda/ 2022-02-18T11:37:22+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-on-virtual-annual-general-meeting-2021/ 2022-02-18T11:37:31+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-half-year-results-for-2021/ 2022-02-18T11:37:40+00:00 https://formycon.metamove.net/en/blog/press-release/formycons-covid-19-drug-fyb207-wins-prestigious-pharma-trend-image-innovation-award-2021/ 2022-02-18T11:37:50+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-on-the-status-of-fyb207-development/ 2022-02-18T11:37:58+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-bioeq-announce-submission-of-the-biologics-license-application-bla-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-u-s-food-and-drug-administration-fda/ 2022-02-18T11:38:10+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-receives-euro-12-7-million-grant-for-further-development-of-covid-19-drug-fyb207-as-part-of-the-bavarian-therapy-strategy-to-combat-the-covid-19-pandemic/ 2022-02-18T11:38:20+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-financial-results-for-the-first-quarter-of-2021/ 2022-02-18T11:38:29+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-bioeq-announce-submission-of-the-marketing-authorization-application-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-european-medicines-agency-ema/ 2022-02-18T11:38:39+00:00 https://formycon.metamove.net/en/blog/press-release/teva-pharmaceutical-industries-ltd-becomes-strategic-partner-for-the-commercialization-of-fyb201-formycons-biosimilar-candidate-to-lucentisr1-ranibizumab-in-europe-canada-israel-and-new-zeala/ 2022-02-18T11:38:50+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-conclusion-of-exclusive-commercialization-agreement-between-bioeq-ag-and-teva-pharmaceutical-industries-ltd-for-fyb201-in-europe-canada-israel-and-new-zealand/ 2022-02-18T11:39:01+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-annual-financial-statements-for-the-2020-financial-year/ 2022-02-18T11:39:12+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-receives-approval-for-early-action-for-covid-19-drug-fyb207-as-part-of-a-grant-from-the-bavarian-ministry-of-economic-affairs-regional-development-and-energy-stmwi/ 2022-02-18T11:39:23+00:00 https://formycon.metamove.net/en/blog/press-release/formycons-covid-19-drug-fyb207-even-more-efficient-against-sars-cov-2-mutant-b-1-1-7/ 2022-02-18T11:39:35+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-leukocare-cooperate-in-the-development-of-high-quality-biopharmaceuticals/ 2022-02-18T11:39:46+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-confirms-bla-submission-strategy-and-timeline-for-its-lucentisr-biosimilar-candidate-fyb201-following-consultation-with-the-fda/ 2022-02-18T11:39:55+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-receives-positive-scientific-advice-from-paul-ehrlich-institute-for-the-covid-19-drug-fyb207-and-assures-gmp-manufacturing-capacities/ 2022-02-18T11:40:12+00:00 https://formycon.metamove.net/en/blog/press-release/formycons-scientific-collaboration-partners-present-fyb207-results-at-international-keystone-symposium/ 2022-02-18T11:40:21+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-on-virtual-annual-general-meeting-2020/ 2022-02-18T11:41:00+00:00 https://formycon.metamove.net/en/blog/press-release/innovative-sars-cov-2-blocker-from-formycon-completely-prevents-infection-of-cells/ 2022-02-18T11:41:10+00:00 https://formycon.metamove.net/en/blog/press-release/chief-operating-officer-dr-stefan-glombitza-appointed-to-formycon-ags-management-board-for-another-four-years/ 2022-02-18T11:41:23+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-its-nine-month-figures-for-2020/ 2022-02-18T11:41:34+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-bioeq-announce-launch-of-phase-iii-study-of-fyb202-a-biosimilar-candidate-for-stelarar-ustekinumab/ 2022-02-18T11:41:43+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-informs-about-the-modified-bla-submission-strategy-for-its-lucentisr-biosimilar-candidate-fyb201/ 2022-02-18T11:41:53+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-virtual-annual-general-meeting-for-december-10-2020/ 2022-02-18T11:42:04+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-receives-funding-for-covid-19-drug-research-from-the-bavarian-research-foundation/ 2022-02-18T11:42:18+00:00 https://formycon.metamove.net/en/blog/press-release/strategic-investor-active-ownership-group-subscribes-for-cash-capital-increase-of-eur-25-75-million/ 2022-02-18T11:42:28+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-places-cash-capital-increase-of-25-75-million-euros-with-strategic-investor/ 2022-02-18T11:42:40+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-half-year-results-for-2020/ 2022-02-18T11:42:51+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-bioeq-enroll-first-patient-in-phase-iii-study-with-aflibercept-biosimilar-fyb203/ 2022-02-18T11:43:01+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-financial-results-for-the-first-quarter-of-2020/ 2022-02-18T11:43:13+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-annual-financial-statements-for-the-2019-financial-year/ 2022-02-18T11:43:22+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-update-on-biosimilar-programs/ 2022-02-18T11:43:32+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-is-postponing-the-general-assembly-into-the-fourth-quarter-of-2020-to-maintain-the-possibility-of-an-event-in-person/ 2022-02-18T11:43:44+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-starts-antibody-based-drug-development-for-covid-19/ 2022-02-18T11:43:54+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-informs-about-the-current-status-of-the-bla-review-process-of-the-lucentis-biosimilar-candidate-fyb201/ 2022-02-18T11:44:04+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-its-nine-month-figures-for-2019/ 2022-02-18T11:44:16+00:00 https://formycon.metamove.net/en/blog/press-release/bioeq-ip-ag-exclusively-licenses-us-marketing-rights-for-fyb201-to-coherus-biosciences-inc/ 2022-02-18T11:44:37+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-start-of-phase-i-clinical-trial-with-ustekinumab-biosimilar-candidate-fyb202/ 2022-02-18T11:44:47+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-half-year-results-for-2019/ 2022-02-18T11:44:56+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-on-annual-general-meeting-2019/ 2022-02-18T11:45:08+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-further-course-of-capital-measure/ 2022-02-18T11:45:21+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-figures-for-the-first-quarter-of-2019/ 2022-02-18T11:45:31+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-latest-status-of-capital-increase/ 2022-02-18T11:45:43+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-successful-2018-financial-year/ 2022-02-18T11:45:53+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-news-on-development-portfolio/ 2022-02-18T11:46:04+00:00 https://formycon.metamove.net/en/blog/press-release/strategic-investor-m-and-h-equity-ag-subscribes-cash-capital-increase-of-euro-17-3-million/ 2022-02-18T11:46:17+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-places-cash-capital-increase-of-eur-17-3-million-with-institutional-investor/ 2022-02-18T11:46:27+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-releases-updates-on-development-programs-and-milestones/ 2022-02-18T11:46:55+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-nine-month-figures-for-2018/ 2022-02-18T11:47:03+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-financial-and-operating-results-for-the-first-half-year-of-2018/ 2022-02-18T11:47:13+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-appoints-development-and-production-expert-thomas-siklosi-to-the-advisory-board/ 2022-02-18T11:47:24+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-with-significant-growth-in-turnover-and-earnings-in-the-first-quarter-of-2018-2/ 2022-02-18T11:47:33+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-with-successful-2017-financial-year-2/ 2022-02-18T11:47:43+00:00 https://formycon.metamove.net/en/blog/press-release/biosimilar-candidate-fyb201-shows-efficacy-comparable-to-the-reference-product-in-phase-iii-study/ 2022-02-18T11:47:54+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-bioeq-achieve-important-milestone-biosimilar-ranibizumab-candidate-fyb201-shows-efficacy-comparable-to-the-reference-product-in-phase-iii-study/ 2022-02-18T11:48:05+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ranks-7th-in-the-financial-times-list-of-europes-1000-strongest-growing-companies/ 2022-02-18T11:48:15+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-aristo-pharma-are-founding-a-joint-venture-for-the-development-of-fyb202-2/ 2022-02-18T11:48:26+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-operating-and-financial-results-for-the-third-quarter-of-2017/ 2022-02-18T11:48:41+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-sets-course-for-the-future-and-confirms-management-board-members-until-mid-2022/ 2022-02-18T11:48:51+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-financial-and-operating-results-for-the-first-half-year-of-2017/ 2022-02-18T11:49:01+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-signs-term-sheet-for-development-of-fyb202-and-executes-capital-increase-2/ 2022-02-18T11:49:10+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-figures-for-the-first-quarter-of-2017-2/ 2022-02-18T11:49:21+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-details-of-further-pipeline-product-fyb202-is-a-biosimilar-candidate-for-stelara-ustekinumab/ 2022-02-18T11:49:30+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-with-successful-2016-financial-year/ 2022-02-18T11:49:42+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-plans-change-in-new-sme-stock-exchange-segment-scale/ 2022-02-18T11:49:51+00:00 https://formycon.metamove.net/en/blog/press-release/focus-magazine-lists-formycon-as-growth-champion-repeatedly-2/ 2022-02-18T11:50:03+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-makes-good-progress-in-first-nine-months-of-2016/ 2022-02-18T11:50:13+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-wins-award-from-stifterverband-for-innovative-strength/ 2022-02-18T11:50:24+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-first-half-2016-financial-and-operating-results/ 2022-02-18T11:50:33+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-expands-board-and-appoints-pharma-top-manager-dr-stefan-glombitza-as-chief-operating-officer/ 2022-02-18T11:50:44+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ceo-dr-carsten-brockmeyer-once-again-honored-as-one-of-the-worlds-most-influential-people-in-the-medicines-industry/ 2022-02-18T11:50:54+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-figures-for-the-first-quarter-of-2016/ 2022-02-18T11:51:02+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ends-2015-fiscal-year-with-successful-results/ 2022-02-18T11:51:11+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-discloses-details-on-second-pipeline-product-fyb203-is-a-biosimilar-for-eylea-aflibercept/ 2022-02-18T11:51:20+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-bioeq-enroll-first-patient-in-pivotal-phase-iii-study-with-biosimilar-ranibizumab-fyb201/ 2022-02-18T11:51:30+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-appoints-biotech-expert-professor-johannes-buchner-to-the-advisory-board/ 2022-02-18T11:51:39+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-files-multiple-patent-applications-for-the-pharmaceutical-formulation-and-delivery-of-intraocular-vegf-antagonists/ 2022-02-18T11:51:49+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-results-for-first-nine-months-of-2015/ 2022-02-18T12:04:56+00:00 https://formycon.metamove.net/en/blog/press-release/global-strategic-partners-bioeq-and-formycon-initiate-pivotal-phase-iii-clinical-trial-with-their-lucentis-biosimilar/ 2022-02-18T12:05:14+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-positive-financial-results-for-first-half-of-2015/ 2022-02-18T12:05:24+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-receives-favorable-scientific-advice-from-u-s-food-and-drug-administration-for-its-partnered-biosimilar-candidate-fyb201/ 2022-02-18T12:05:35+00:00 https://formycon.metamove.net/en/blog/press-release/results-announced-for-1q-2015-forecast-raised-for-full-year-2015/ 2022-02-18T12:05:46+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-signs-licensing-agreement-for-its-fyb203-biosimilar/ 2022-02-18T12:05:57+00:00 https://formycon.metamove.net/en/blog/press-release/carsten-brockmeyer-belongs-to-the-top-20-most-influential-people-in-the-global-medicine-maker-power-list-2015/ 2022-02-18T12:06:07+00:00 https://formycon.metamove.net/en/blog/press-release/reappointment-of-board-member-dr-nicolas-combe/ 2022-02-18T12:06:17+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-successfully-completes-capital-increase-from-approved-capital/ 2022-02-18T12:06:27+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-group-announces-preliminary-results-for-fiscal-year-2014/ 2022-02-18T12:06:40+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-announces-successful-gmp-inspection-and-the-start-of-us-fda-scientific-advice-procedure-for-its-out-licensed-biosimilar-fyb201/ 2022-02-18T12:06:54+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-moves-planned-start-of-pivotal-phase-iii-study-for-its-first-biosimilar-product-fyb201-forward-to-3q-2015/ 2022-02-18T12:07:04+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-releases-nine-month-figures-for-2014/ 2022-02-18T12:07:13+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-announces-its-results-for-the-first-half-of-2014/ 2022-02-18T12:07:22+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-commences-development-of-its-third-product-seeing-this-as-confirmation-of-its-pioneering-position-in-the-third-wave-of-biosimilar-drugs/ 2022-02-18T12:07:34+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-announces-financial-results-of-fiscal-year-2013-and-first-quarter-results-of-fiscal-year-2014/ 2022-02-18T12:07:45+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-strong-partner-increases-marketing-potential-for-the-first-biosimilar-development-project/ 2022-02-18T12:07:54+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-appoints-top-us-pharmaceuticals-manager-bernhard-hampl-to-the-advisory-board/ 2022-02-18T12:08:03+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-licensing-out-of-the-first-biosimilar-development-project-already-enables-extension-of-the-product-pipeline-as-of-2014/ 2022-02-18T12:08:13+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-signs-first-biosimilar-licensing-agreement-with-santo-holding-gmbh-2/ 2022-02-18T12:08:23+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-successfully-completes-capital-increase/ 2022-02-18T12:08:33+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-today-has-announced-the-appointment-of-gerhard-schaefer-and-simon-sturge-to-formycons-advisory-board/ 2022-02-18T12:08:41+00:00 https://formycon.metamove.net/blog/press-release/chief-operating-officer-dr-stefan-glombitza-fuer-vier-weitere-jahre-zum-vorstand-der-formycon-ag-bestellt/ 2022-02-18T14:15:16+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-neunmonatsergebnis-fuer-2020/ 2022-02-18T14:22:09+00:00 https://formycon.metamove.net/blog/press-release/formycon-informiert-ueber-modifizierte-einreichungsstrategie-fuer-lucentisr-biosimilar-kandidat-fyb201/ 2022-02-18T14:26:32+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-virtuellen-hauptversammlung-am-10-dezember-2020-ein/ 2022-02-18T14:27:35+00:00 https://formycon.metamove.net/blog/press-release/formycon-platziert-barkapitalerhoehung-in-hoehe-von-2575-millionen-euro-bei-strategischem-investor/ 2022-02-18T14:31:34+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-halbjahresergebnis-2020-bekannt/ 2022-02-18T14:35:23+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-finanzergebnis-fuer-das-erste-quartal-2020/ 2022-02-18T14:36:38+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroeffentlicht-jahresabschluss-fuer-das-geschaeftsjahr-2019/ 2022-02-18T14:37:48+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-update-zu-biosimilar-programmen-bekannt/ 2022-02-18T14:39:46+00:00 https://formycon.metamove.net/blog/press-release/formycon-verschiebt-hauptversammlung-in-das-vierte-quartal-2020-um-moeglichkeit-einer-praesenzveranstaltung-zu-wahren/ 2022-02-18T14:40:35+00:00 https://formycon.metamove.net/blog/press-release/formycon-informiert-ueber-aktuellen-status-im-zulassungsprozess-des-lucentis-biosimilar-kandidaten-fyb201/ 2022-02-18T14:41:44+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-athos-kg-fuhren-entwicklungaktivitaten-durch-ubernahme-von-biosimilar-assets-in-langfristiger-strategischer-partnerschaft-zusammen/ 2022-03-29T15:42:39+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-athos-kg-merge-development-activities-through-the-acquisition-of-biosimilar-assets-in-a-long-term-strategic-partnership/ 2022-03-29T18:41:37+00:00 https://formycon.metamove.net/blog/press-release/formycon-ubernimmt-biosimilar-assets-fyb201-und-fyb202-und-starkt-position-im-globalen-wachstumsmarkt-biosimilars-durch-langfristige-partnerschaft-mit-der-athos-kg/ 2022-03-31T08:21:08+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-is-acquiring-the-biosimilar-assets-fyb201-and-fyb202-and-strengthening-its-position-in-the-global-growth-market-of-biosimilars-through-long-term-partnership-with-athos-kg/ 2022-03-31T08:26:09+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-virtuelle-hauptversammlung-2020/ 2022-06-14T13:06:06+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroeffentlicht-halbjahresergebnis-2021/ 2022-06-14T13:09:49+00:00 https://formycon.metamove.net/blog/press-release/die-europaische-kommission-hat-fyb201-ranivisio1-ranivisio-ranibizumab-ein-biosimilar-fur-lucentis2-zugelassen/ 2022-09-01T11:48:41+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-die-eu-zulassung-von-fyb201-ranivisio1-einem-biosimilar-fur-lucentis2-bekannt/ 2022-09-01T11:48:49+00:00 https://formycon.metamove.net/blog/press-release/formycons-ustekinumab-biosimilar-kandidat-fyb202-zeigt-in-phase-iii-studie-vergleichbare-wirksamkeit-zum-referenzprodukt-stelara/ 2022-09-01T11:49:01+00:00 https://formycon.metamove.net/blog/press-release/u-s-food-and-drug-administration-fda-hat-fyb201-cimerlitm1-ranibizumab-eqrn-als-erstes-biosimilar-fur-lucentis2-zur-automatischen-substitution-zugelassen/ 2022-09-01T11:49:09+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-fda-zulassung-von-fyb201-cimerlitm1-ranibizumab-eqrn-als-austauschbares-biosimilar-fur-lucentis2-bekannt/ 2022-09-01T11:49:16+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-uber-virtuelle-hauptversammlung-2022-2/ 2022-09-01T11:49:23+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-gibt-anderung-des-wahlvorschlags-eines-aufsichtsratsmitglieds-top-9-im-rahmen-der-ordentlichen-hauptversammlung-am-30-juni-2022-bekannt/ 2022-09-01T11:49:31+00:00 https://formycon.metamove.net/blog/press-release/fyb201-formycons-biosimilar-fur-lucentis-ranibizumab-erhalt-chmp-empfehlung-der-ema/ 2022-09-01T11:49:40+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-formycon-berichtet-finanzergebnis-fur-das-erste-quartal-2022-und-gibt-entwicklungsstart-zweier-neuer-biosimilar-kandidaten-fyb208-und-fyb209-bekannt/ 2022-09-01T11:49:50+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroffentlicht-update-zu-entwicklungsprojekten/ 2022-09-01T11:49:56+00:00 https://formycon.metamove.net/blog/press-release/formycon-ernennt-dr-stefan-glombitza-zum-ceo-und-stellt-mit-berufung-der-beiden-erfahrenen-pharma-manager-nicola-mikulcik-und-dr-andreas-seidl-in-den-vorstand-die-weichen-fur-die-zukunft/ 2022-09-01T11:50:03+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-veranderungen-im-vorstand-bekannt/ 2022-09-01T11:50:10+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroffentlicht-jahresabschluss-fur-das-geschaftsjahr-2021/ 2022-09-01T11:50:16+00:00 https://formycon.metamove.net/blog/press-release/britische-arzneimittelbehorde-mhra-erteilt-marktzulassung-fur-fyb201-formycons-biosimilar-fur-lucentis1-das-von-teva-unter-dem-namen-ongavia-vermarktet-werden-wird/ 2022-09-01T11:50:23+00:00 https://formycon.metamove.net/blog/press-release/fyb201-formycons-biosimilar-fur-lucentis1-erhalt-marktzulassung-in-grosbritannien/ 2022-09-01T11:50:29+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-und-athos-kg-geben-abschluss-der-transaktion-zur-ubernahme-der-biosimilar-assets-fyb201-und-fyb202-sowie-der-bioeq-gmbh-bekannt/ 2022-09-01T11:50:38+00:00 https://formycon.metamove.net/en/blog/press-release/european-commission-approves-fyb201-ranivisio1-ranivisio-ranibizumab-a-biosimilar-to-lucentis2/ 2022-09-01T11:55:49+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-eu-approval-of-fyb201-ranivisio1-a-biosimilar-to-lucentis2/ 2022-09-01T11:55:56+00:00 https://formycon.metamove.net/en/blog/press-release/formycons-biosimilar-ustekinumab-candidate-fyb202-shows-comparable-efficacy-to-reference-product-stelara-in-phase-iii-study/ 2022-09-01T11:56:03+00:00 https://formycon.metamove.net/en/blog/press-release/u-s-food-and-drug-administration-fda-approved-fyb201-cimerlitm1-ranibizumab-eqrn-the-first-and-only-biosimilar-interchangeable-with-lucentis2/ 2022-09-01T11:56:10+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-fda-approval-of-fyb201-cimerlitm1-ranibizumab-eqrn-as-a-biosimilar-interchangeable-with-lucentis2/ 2022-09-01T11:56:16+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-on-virtual-annual-general-meeting-2022/ 2022-09-01T11:56:22+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-announces-amendment-to-the-proposal-for-election-of-a-supervisory-board-member-agenda-item-9-in-the-context-of-the-annual-general-meeting-on-june-30-2022/ 2022-09-01T11:56:28+00:00 https://formycon.metamove.net/en/blog/press-release/fyb201-formycons-biosimilar-for-lucentis-ranibizumab-receives-chmp-recommendation-from-ema/ 2022-09-01T11:56:34+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-first-quarter-2022-financial-results-and-announces-development-start-of-two-new-biosimilar-candidates-fyb208-and-fyb209/ 2022-09-01T11:56:40+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-update-on-development-projects/ 2022-09-01T11:56:46+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-appoints-dr-stefan-glombitza-as-ceo-and-sets-the-course-for-the-future-by-appointing-the-two-experienced-pharmaceutical-managers-nicola-mikulcik-and-dr-andreas-seidl-to-the-executive-board/ 2022-09-01T11:56:53+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-changes-to-its-executive-board/ 2022-09-01T11:56:59+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-annual-financial-statements-for-the-2021-financial-year/ 2022-09-01T11:57:05+00:00 https://formycon.metamove.net/en/blog/press-release/united-kingdom-medicines-and-healthcare-products-regulatory-agency-mhra-grants-marketing-authorization-for-fyb201-formycons-biosimilar-for-lucentis1-to-be-commercialized-by-teva-as-ongavia/ 2022-09-01T11:57:11+00:00 https://formycon.metamove.net/en/blog/press-release/fyb201-formycons-biosimilar-for-lucentis1-achieves-marketing-authorization-in-united-kingdom/ 2022-09-01T11:57:18+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-and-athos-kg-announce-closing-of-transaction-to-acquire-biosimilar-assets-fyb201-and-fyb202-as-well-as-bioeq-gmbh/ 2022-09-01T11:57:24+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroffentlicht-vorlaufige-zahlen-zum-ersten-halbjahr-2022/ 2022-09-06T05:35:18+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-preliminary-figures-for-the-first-half-of-2022/ 2022-09-06T05:35:18+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroffentlicht-details-zu-weiterem-pipelineprojekt-fyb206-ist-ein-biosimilar-kandidat-fur-keytruda-pembrolizumab/ 2022-09-19T05:35:15+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-details-of-a-previously-undisclosed-pipeline-project-fyb206-is-a-biosimilar-candidate-for-keytruda-pembrolizumab/ 2022-09-19T06:39:10+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-final-figures-for-the-first-half-of-2022/ 2022-10-28T05:31:06+00:00 https://formycon.metamove.net/blog/press-release/formycon-legt-endgueltige-zahlen-fuer-das-erste-halbjahr-2022-vor/ 2022-10-28T05:31:06+00:00 https://formycon.metamove.net/blog/press-release/fyb207-zeigt-in-praeklinischen-studien-laengere-halbwertszeit-und-verbesserte-wirksamkeit/ 2022-11-03T06:31:13+00:00 https://formycon.metamove.net/en/blog/press-release/fyb207-shows-longer-half-life-and-improved-efficacy/ 2022-11-03T06:31:13+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-neunmonatsergebnis-fuer-2022/ 2022-11-25T06:31:45+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-its-nine-month-figures-for-2022/ 2022-11-25T06:31:45+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-plans-capital-increase-of-up-to-5-of-the-share-capital/ 2023-02-01T16:42:25+00:00 https://formycon.metamove.net/blog/press-release/kommerzialisierungsvereinbarung-mit-fresenius-kabi-fuer-fyb202/ 2023-02-01T16:42:19+00:00 https://formycon.metamove.net/en/blog/press-release/global-license-agreement-with-fresenius-kabi-for-fyb202/ 2023-02-01T16:42:19+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-plant-kapitalerhoehung-im-volumen-von-bis-zu-5-des-grundkapitals/ 2023-02-01T16:42:25+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-upsizes-capital-increase-from-authorized-capital-following-strong-demand/ 2023-02-01T22:35:15+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-erhoeht-kapitalerhoehung-aus-genehmigtem-kapital-aufgrund-hoher-nachfrage/ 2023-02-01T22:38:48+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-gibt-ergebnis-der-privatplatzierung-bekannt-und-setzt-den-platzierungspreis-fuer-die-neuen-aktien-aus-der-kapitalerhoehung-fest/ 2023-02-02T06:32:53+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-announces-result-of-private-placement-and-sets-placement-price-for-the-new-shares-from-the-capital-increase/ 2023-02-02T06:32:53+00:00 https://formycon.metamove.net/blog/press-release/formycons-aflibercept-biosimilar-kandidat-fyb203-zeigt-in-phase-iii-studie-vergleichbare-wirksamkeit-zum-referenzprodukt-eylea1/ 2023-02-06T06:32:55+00:00 https://formycon.metamove.net/en/blog/press-release/formycons-aflibercept-biosimilar-kandidat-fyb203-zeigt-in-phase-iii-studie-vergleichbare-wirksamkeit-zum-referenzprodukt-eylea1/ 2023-02-06T06:32:55+00:00 https://formycon.metamove.net/blog/press-release/enno-spillner-wird-finanzvorstand-cfo-der-formycon-ag/ 2023-02-07T06:32:55+00:00 https://formycon.metamove.net/en/blog/press-release/enno-spillner-appointed-chief-financial-officer-cfo-of-formycon-ag/ 2023-02-07T06:32:55+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-conclude-global-commercialization-partnership-for-fyb202/ 2023-02-10T09:32:06+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-binding-term-sheet-between-klinge-biopharma-and-coherus-biosciences-for-the-exclusive-commercialization-of-fyb203-a-biosimilar-candidate-to-eylea1-in-the-united-states/ 2023-02-10T09:37:05+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-verbindliches-term-sheet-zwischen-klinge-biopharma-und-coherus-biosciences-fuer-die-exklusive-vermarktung-von-fyb203-einem-biosimilar-kandidaten-fuer-eylea1-in-den-usa-bekannt/ 2023-02-10T09:39:02+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-erfolgreiche-klinische-phase-i-studie-fuer-biosimilar-kandidat-fyb202-ustekinumab-bekannt-und-schliesst-klinische-entwicklung-ab/ 2023-04-25T05:05:39+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-successful-results-of-phase-i-clinical-trial-for-ustekinumab-biosimilar-candidate-fyb202-and-concludes-clinical-development/ 2023-04-25T05:05:39+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-fresenius-kabi-schliessen-globale-kommerzialisierungspartnerschaft-fuer-fyb202/ 2023-04-25T09:45:03+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-results-for-financial-year-2022/ 2023-04-27T05:32:03+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroeffentlicht-ergebnisse-fuer-das-geschaeftsjahr-2022/ 2023-04-27T06:17:52+00:00 https://formycon.metamove.net/blog/press-release/formycon-kuendigt-teilnahme-an-internationalen-investorenkonferenzen-in-q2-2023-an/ 2023-05-10T05:32:07+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-participation-in-international-investor-conferences-in-q2-2023/ 2023-05-10T05:32:07+00:00 https://formycon.metamove.net/blog/press-release/ergebnisse-q1-2023/ 2023-05-30T05:35:42+00:00 https://formycon.metamove.net/en/blog/press-release/q1-2023-results/ 2023-05-30T05:35:42+00:00 https://formycon.metamove.net/blog/press-release/formycon-auf-der-jefferies-global-healthcare-konferenz-2023-praesentation-im-livestream/ 2023-06-06T11:21:01+00:00 https://formycon.metamove.net/en/blog/press-release/livestream-jefferies-global-healthcare-2023/ 2023-06-06T11:21:07+00:00 https://formycon.metamove.net/blog/press-release/fda-einreichung-fyb203/ 2023-06-29T05:35:30+00:00 https://formycon.metamove.net/en/blog/press-release/fda-submission-for-fyb203/ 2023-06-29T05:35:30+00:00 https://formycon.metamove.net/en/blog/press-release/reports-on-the-regular-annual-general-meeting/ 2023-07-26T05:34:21+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-ordentliche-hauptversammlung/ 2023-07-26T05:36:18+00:00 https://formycon.metamove.net/en/blog/press-release/fyb202-settlement-agreement-us/ 2023-08-07T06:02:49+00:00 https://formycon.metamove.net/blog/press-release/fyb202-settlement-vereinbarung-us/ 2023-08-07T06:02:49+00:00 https://formycon.metamove.net/blog/press-release/h1-telefonkonferenz/ 2023-08-23T05:32:29+00:00 https://formycon.metamove.net/en/blog/press-release/h1-earnings-call/ 2023-08-23T05:32:29+00:00 https://formycon.metamove.net/blog/press-release/file-acceptance-fyb203/ 2023-08-29T05:31:51+00:00 https://formycon.metamove.net/en/blog/press-release/file-acceptance-fyb203/ 2023-08-29T05:31:51+00:00 https://formycon.metamove.net/blog/press-release/halbjahresbericht-2023/ 2023-08-30T05:31:40+00:00 https://formycon.metamove.net/en/blog/press-release/half-year-report-2023/ 2023-08-30T05:31:40+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-announce-european-medicines-agency-acceptance-of-the-marketing-authorization-application-for-fyb202-an-ustekinumab-biosimilar-candidate/ 2023-09-29T05:32:47+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-fresenius-kabi-geben-annahme-des-zulassungsantrags-durch-die-europaeische-arzneimittel-agentur-ema-fuer-fyb202-einen-ustekinumab-biosimilar-kandidaten-bekannt/ 2023-09-29T05:32:47+00:00 https://formycon.metamove.net/blog/press-release/25-prozent-marktanteil-fuer-fyb201-in-den-usa/ 2023-10-10T05:31:20+00:00 https://formycon.metamove.net/en/blog/press-release/25-percent-market-share-for-fyb201-in-the-us/ 2023-10-10T05:31:20+00:00 https://formycon.metamove.net/blog/press-release/formycon-veranstaltet-telefonkonferenz-zum-neunmonatsergebnis-2023-und-praesentiert-auf-weiteren-investorenkonferenzen/ 2023-11-10T05:35:19+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-hosts-conference-call-on-nine-month-figures-2023-and-presents-at-further-investor-conferences/ 2023-11-10T05:35:19+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-nine-month-results-for-2023/ 2023-11-13T06:42:59+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroeffentlicht-neunmonatsergebnis-fuer-2023/ 2023-11-13T06:43:20+00:00 https://formycon.metamove.net/blog/press-release/ema-einreichung-fyb203/ 2023-11-27T06:32:10+00:00 https://formycon.metamove.net/en/blog/press-release/ema-submission-fyb203/ 2023-11-27T06:32:10+00:00 https://formycon.metamove.net/en/blog/press-release/file-acceptance-fyb202/ 2023-11-30T06:32:08+00:00 https://formycon.metamove.net/blog/press-release/file-acceptance-fyb202/ 2023-11-30T06:32:08+00:00 https://formycon.metamove.net/en/blog/press-release/investorconferences-q1-2024/ 2023-12-05T06:32:50+00:00 https://formycon.metamove.net/blog/press-release/investorenkonferenzen-q1-2024/ 2023-12-05T06:32:50+00:00 https://formycon.metamove.net/blog/press-release/kanada-zulassung-fyb201/ 2023-12-07T06:32:32+00:00 https://formycon.metamove.net/en/blog/press-release/canada-approval-fyb201/ 2023-12-07T06:32:32+00:00 https://formycon.metamove.net/blog/press-release/maa-acceptance-fyb203/ 2023-12-27T06:32:43+00:00 https://formycon.metamove.net/en/blog/press-release/maa-acceptance-fyb203/ 2023-12-27T06:32:43+00:00 https://formycon.metamove.net/en/blog/press-release/gedeon-richter-becomes-strategic-investor-of-formycon-via-equity-investment/ 2024-02-21T18:24:08+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-resolves-on-cash-capital-increase-of-eur-82-84-million/ 2024-02-21T18:24:17+00:00 https://formycon.metamove.net/en/blog/press-release/fyb201-us-uptake-dec2023/ 2024-02-21T18:24:25+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-presents-at-jpm24/ 2024-02-21T18:24:38+00:00 https://formycon.metamove.net/blog/press-release/gedeon-richter-wird-strategischer-investor-von-formycon-im-rahmen-einer-kapitalbeteiligung/ 2024-02-21T18:24:51+00:00 https://formycon.metamove.net/blog/press-release/formycon-beschliesst-barkapitalerhoehung-in-hoehe-von-eur-8284-mio/ 2024-02-21T18:24:58+00:00 https://formycon.metamove.net/blog/press-release/fyb201-us-uptake-dec2023/ 2024-02-21T18:25:04+00:00 https://formycon.metamove.net/blog/press-release/formycon-praesentiert-auf-jpm24/ 2024-02-21T18:25:11+00:00 https://formycon.metamove.net/en/blog/press-release/fyb201-ranibizumab-keeps-gaining-momentum-with-approvals-and-launches-in-the-mena-region/ 2024-03-11T06:35:00+00:00 https://formycon.metamove.net/blog/press-release/zulassungen-mena-region/ 2024-03-11T06:35:00+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-reach-settlement-agreement-for-ustekinumab-biosimilar-candidate-fyb202-in-europe-and-canada/ 2024-03-18T09:02:44+00:00 https://formycon.metamove.net/blog/press-release/formycons-ranibizumab-biosimilar-fyb201-cimerli-erreicht-im-dezember-2023-einen-marktanteil-von-38-in-den-usa/ 2024-03-18T09:02:44+00:00 https://formycon.metamove.net/en/blog/press-release/fyb201-launch-ca-and-ch/ 2024-04-11T05:32:37+00:00 https://formycon.metamove.net/blog/press-release/fyb201-launch-ca-und-ch/ 2024-04-11T05:32:37+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-veroeffentlicht-vorlaeufige-geschaeftszahlen-fuer-das-geschaeftsjahr-2023/ 2024-04-12T17:35:07+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-publishes-preliminary-figures-for-the-2023-financial-year/ 2024-04-12T17:35:07+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-vorlaeufige-zahlen-fuer-das-geschaeftsjahr-2023-und-uebertrifft-prognose/ 2024-04-12T20:20:15+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-preliminary-results-for-the-financial-year-2023-and-exceeds-forecast/ 2024-04-12T20:20:15+00:00 https://formycon.metamove.net/blog/press-release/earnings-call-fy2023/ 2024-04-22T05:35:37+00:00 https://formycon.metamove.net/en/blog/press-release/earnings-call-fy2023/ 2024-04-22T05:35:37+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroeffentlicht-testierten-jahresabschluss-fuer-das-geschaeftsjahr-2023/ 2024-04-25T05:32:17+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-audited-annual-results-for-the-financial-year-2023/ 2024-04-25T05:32:17+00:00 https://formycon.metamove.net/blog/press-release/formycon-veranstaltet-telefonkonferenz-zu-den-ergebnissen-des-ersten-quartals-2024/ 2024-05-02T05:32:58+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-hosts-conference-call-on-the-results-of-the-first-quarter-2024/ 2024-05-02T05:32:58+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-ordentlichen-hauptversammlung-am-12-juni-2024-in-muenchen-ein/ 2024-05-07T09:01:04+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-the-annual-general-meeting-on-june-12-2024-in-munich/ 2024-05-07T09:01:04+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-erfolgreiches-operatives-geschaeft-und-finanzzahlen-fuer-das-erste-quartal-2024/ 2024-05-08T05:31:06+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-on-successful-operating-business-and-financial-figures-for-the-first-quarter-of-2024/ 2024-05-08T05:31:06+00:00 https://formycon.metamove.net/en/blog/press-release/ms-pharma-becomes-partner-for-the-commercialization-of-fyb203-formycons-biosimilar-candidate-to-eylea-aflibercept-in-the-mena-region/ 2024-05-15T05:33:11+00:00 https://formycon.metamove.net/blog/press-release/ms-pharma-wird-kommerzialisierungspartner-fuer-fyb203-formycons-eylea-biosimilar-kandidat-aflibercept-in-der-mena-region/ 2024-05-15T05:33:11+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-starts-clinical-development-program-for-fyb206-a-biosimilar-candidate-for-immuno-oncology-blockbuster-drug-keytruda/ 2024-06-13T05:32:36+00:00 https://formycon.metamove.net/blog/press-release/formycon-startet-klinisches-programm-fuer-fyb206-einen-biosimilar-kandidaten-fuer-das-immun-onkologische-blockbuster-medikament-keytruda/ 2024-06-13T05:32:36+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-on-the-results-of-the-annual-general-meeting/ 2024-06-13T13:30:06+00:00 https://formycon.metamove.net/blog/press-release/formycon-informiert-ueber-die-ergebnisse-der-ordentlichen-hauptversammlung/ 2024-06-13T15:30:56+00:00 https://formycon.metamove.net/en/blog/press-release/fda-grants-approval-for-eylea-biosimilar-fyb203/ 2024-06-28T21:53:32+00:00 https://formycon.metamove.net/blog/press-release/fda-erteilt-zulassung-fuer-eylea1-biosimilar-fyb203-ahzantive2-aflibercept-mrbb/ 2024-06-28T21:53:43+00:00 https://formycon.metamove.net/blog/press-release/formycon-erhaelt-fda-zulassung-fuer-fyb203-ahzantive/ 2024-07-01T04:52:11+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-receives-fda-approval-for-fyb203-ahzantive/ 2024-07-01T04:52:11+00:00 https://formycon.metamove.net/en/blog/press-release/fyb202-receives-positive-chmp-opinion-from-ema/ 2024-07-26T09:20:19+00:00 https://formycon.metamove.net/blog/press-release/fyb202-erhaelt-chmp-empfehlung-der-ema/ 2024-07-26T09:21:11+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-receive-positive-chmp-opinion-for-fyb202/ 2024-07-26T10:03:58+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-fresenius-kabi-erhalten-positive-chmp-empfehlung-fuer-fyb202/ 2024-07-26T10:03:58+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-increases-its-outlook-for-the-2024-fiscal-year/ 2024-08-06T10:44:18+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-hebt-prognose-fuer-das-geschaeftsjahr-2024-an/ 2024-08-06T10:44:54+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-conference-call-on-2024-half-year-results-and-announces-participation-in-international-investor-conferences/ 2024-08-07T04:57:59+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-telefonkonferenz-zu-den-ergebnissen-des-ersten-halbjahres-2024-ein-und-gibt-teilnahme-an-internationalen-investorenkonferenzen-bekannt/ 2024-08-07T04:57:59+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-starkes-erstes-halbjahr-mit-zahlreichen-meilensteinen/ 2024-08-13T04:53:17+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-a-strong-first-half-year-with-multiple-milestones-achieved/ 2024-08-13T04:53:17+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-start-der-klinischen-phase-iii-studie-fuer-den-keytruda-biosimilar-kandidaten-fyb206-bekannt/ 2024-09-10T12:05:53+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-start-of-clinical-phase-iii-trial-for-keytruda-biosimilar-candidate-fyb206/ 2024-09-10T12:06:18+00:00 https://formycon.metamove.net/blog/press-release/formycon-praesentiert-klinische-daten-zum-ustekinumab-biosimilar-kandidaten-fyb202-auf-dem-eadv-kongress-in-amsterdam-und-der-ueg-woche-in-wien/ 2024-09-17T04:55:33+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-will-present-clinical-data-on-its-ustekinumab-biosimilar-candidate-fyb202-at-the-eadv-congress-in-amsterdam-and-the-ueg-week-in-vienna/ 2024-09-17T04:55:33+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-fresenius-kabi-erhalten-zulassung-der-europaeischen-kommission-fuer-fyb202-otulfi-ustekinumab-zur-behandlung-schwerwiegender-inflammatorischer-erkrankungen/ 2024-09-27T07:05:02+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-receive-european-commission-approval-for-fyb202-otulfi-ustekinumab-for-the-treatment-of-serious-inflammatory-diseases/ 2024-09-27T07:05:02+00:00 https://formycon.metamove.net/blog/press-release/fda-erteilt-zulassung-fuer-stelara-biosimilar-fyb202-otulfi-ustekinumab-aauz/ 2024-09-27T20:01:40+00:00 https://formycon.metamove.net/en/blog/press-release/fda-grants-approval-for-stelara-biosimilar-fyb202-otulfitm-ustekinumab-aauz/ 2024-09-27T20:01:55+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-receive-fda-approval-for-fyb202-otulfi-ustekinumab-aauz/ 2024-09-30T05:34:57+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-fresenius-kabi-erhalten-fda-zulassung-fuer-fyb202-otulfitm-ustekinumab-aauz/ 2024-09-30T05:34:57+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-published-results-of-analytical-similarity-study-of-biosimilar-candidate-fyb206-and-keytruda-in-peer-reviewed-journal-drugs-in-rd/ 2024-10-16T04:55:35+00:00 https://formycon.metamove.net/blog/press-release/formycon-publiziert-ergebnisse-der-analytischen-studie-zur-vergleichbarkeit-des-biosimilar-kandidaten-fyb206-mit-keytruda-in-der-fachzeitschrift-drugs-in-rd/ 2024-10-16T04:55:35+00:00 https://formycon.metamove.net/blog/press-release/formycon-beantragt-wechsel-in-den-prime-standard-der-frankfurter-wertpapierboerse/ 2024-11-04T05:55:37+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-applies-for-admission-to-the-prime-standard-of-the-frankfurt-stock-exchange/ 2024-11-04T06:54:57+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-extends-management-board-contract-for-ceo-dr-stefan-glombitza-until-2027-and-receives-admission-to-trading-in-the-prime-standard/ 2024-11-11T16:44:35+00:00 https://formycon.metamove.net/blog/press-release/formycon-verlaengert-vorstandsvertrag-fuer-ceo-dr-stefan-glombitza-bis-2027-und-erhaelt-zulassung-fuer-handel-im-prime-standard/ 2024-11-11T16:45:17+00:00 https://formycon.metamove.net/blog/press-release/aflibercept-biosimilar-fyb203-ahzantive-baiama-erhaelt-chmp-empfehlung-der-ema/ 2024-11-15T17:21:28+00:00 https://formycon.metamove.net/en/blog/press-release/aflibercept-biosimilar-fyb203-ahzantive-baiama-receives-positive-chmp-opinion-from-ema/ 2024-11-15T17:21:41+00:00 https://formycon.metamove.net/blog/press-release/formycon-erhaelt-positive-chmp-empfehlung-fuer-fyb203-aflibercept-einen-biosimilar-kandidaten-fuer-eylea-unter-den-markennamen-ahzantive-und-baiama/ 2024-11-18T05:33:03+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-earnings-call-on-the-nine-month-results-2024-and-announces-participation-in-international-investor-conferences/ 2024-11-19T05:32:01+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zum-earnings-call-fuer-das-neunmonatsergebnis-2024-ein-und-gibt-teilnahme-an-internationalen-investorenkonferenzen-bekannt/ 2024-11-19T05:32:01+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-neunmonatsergebnis-2024-und-setzt-wachstumskurs-mit-weiteren-operativen-erfolgen-fort/ 2024-11-28T05:33:30+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-receives-positive-chmp-opinion-for-fyb203-aflibercept-a-biosimilar-candidate-to-eylea-under-the-tradenames-ahzantive-and-baiama/ 2024-11-27T19:22:59+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-nine-month-results-for-2024-and-continues-growth-trajectory-with-further-operational-success/ 2024-11-28T05:33:30+00:00 https://formycon.metamove.net/blog/press-release/formycon-steigt-in-den-sdax-der-deutschen-boerse-auf/ 2024-12-05T11:56:47+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-joins-the-sdax-of-the-german-stock-exchange/ 2024-12-05T11:56:47+00:00 https://formycon.metamove.net/blog/press-release/ms-pharma-wird-kommerzialisierungspartner-fuer-fyb202-ustekinumab-in-der-mena-region/ 2024-12-09T05:32:24+00:00 https://formycon.metamove.net/en/blog/press-release/ms-pharma-becomes-partner-for-the-commercialization-of-fyb202-ustekinumab-in-the-mena-region/ 2024-12-09T05:32:24+00:00 https://formycon.metamove.net/blog/press-release/bio-usawa-wird-vermarktungspartner-von-fyb201-bioucenta-ranibizumab-in-der-region-subsahara-afrika/ 2025-07-08T07:45:09+00:00 https://formycon.metamove.net/blog/press-release/formycon-platziert-erfolgreich-eine-unbesicherte-und-variabel-verzinsliche-anleihe-in-hoehe-von-eur-70-mio/ 2025-07-08T07:45:24+00:00 https://formycon.metamove.net/blog/press-release/formycon-erhoeht-anleihevolumen-nach-ueberzeichnung-anleihe-2025-2029-in-hoehe-von-70-mio-euro-erfolgreich-und-vollstaendig-platziert/ 2025-07-08T07:46:28+00:00 https://formycon.metamove.net/blog/press-release/us-biosimilarspezialist-valorum-biologics-llc-wird-kommerzialisierungspartner-fuer-formycons-eylea-biosimilar-fyb203-ahzantive-aflibercept-mrbb-in-den-vereinigten-staaten-und-kanada/ 2025-07-08T07:46:37+00:00 https://formycon.metamove.net/blog/press-release/starke-nachfrage-nach-formycon-anleihe-2025-2029-fuehrt-zu-verkuerzung-der-angebotsfrist/ 2025-07-08T07:46:45+00:00 https://formycon.metamove.net/blog/press-release/vorzeitiges-ende-der-angebotsfrist-fuer-anleihe-aufgrund-hoher-nachfrage/ 2025-07-08T07:46:51+00:00 https://formycon.metamove.net/blog/press-release/formycon-anleihe-2025-2029-oeffentliche-zeichnung-jetzt-auch-direkt-ueber-die-deutsche-boerse-moeglich/ 2025-07-08T07:46:58+00:00 https://formycon.metamove.net/blog/press-release/ordentliche-hauptversammlung-der-formycon-ag-stimmt-allen-beschlussvorschlaegen-mit-grossen-mehrheiten-zu/ 2025-07-08T07:47:07+00:00 https://formycon.metamove.net/blog/press-release/zeichnung-der-unternehmensanleihe-2025-2029-gestartet/ 2025-07-08T07:47:16+00:00 https://formycon.metamove.net/blog/press-release/formycon-plant-oeffentliche-unternehmensanleihe-zur-unterstuetzung-der-naechsten-wachstumsphase-im-attraktiven-biosimilar-markt/ 2025-07-08T07:47:23+00:00 https://formycon.metamove.net/blog/press-release/formycon-plant-begebung-einer-unbesicherten-und-variabel-verzinslichen-oeffentlich-handelbaren-anleihe-mit-einem-zielvolumen-von-eur-50-mio-zur-unterstuetzung-des-weiteren-unternehmenswachstums/ 2025-07-08T07:47:31+00:00 https://formycon.metamove.net/blog/press-release/lucentis-biosimilar-fyb201-ranivisio-ranibizumab-in-brasilien-zugelassen/ 2025-07-08T07:47:38+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-fresenius-kabi-geben-markteinfuehrung-des-ustekinumab-biosimilars-fyb202-otulfi-in-kanada-bekannt/ 2025-07-08T07:47:45+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-fresenius-kabi-geben-fda-zulassung-von-fyb202-otulfi-ustekinumab-aauz-als-austauschbares-biosimilar-interchangeable-bekannt/ 2025-07-08T07:47:51+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-erfolgreiches-operatives-geschaeft-und-finanzzahlen-fuer-das-erste-quartal-2025/ 2025-07-08T07:47:57+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-telefonkonferenz-zu-den-ergebnissen-des-ersten-quartals-2025-ein-und-gibt-teilnahme-an-internationalen-investorenkonferenzen-bekannt/ 2025-07-08T07:48:04+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-erfolgreiches-geschaeftsjahr-2024-mit-starken-operativen-fortschritten-und-kontinuierlichem-ausbau-der-marktposition/ 2025-07-08T07:48:10+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-telefonkonferenz-zu-den-ergebnissen-des-geschaeftsjahres-2024-ein-und-gibt-teilnahme-an-internationalen-investorenkonferenzen-im-2-quartal-2025-bekannt/ 2025-07-08T07:48:17+00:00 https://formycon.metamove.net/blog/press-release/markteinfuehrung-von-fyb202-otulfi-ustekinumab-aauz-einem-biosimilar-zu-stelara-in-den-usa-und-der-europaeischen-union/ 2025-07-08T07:48:23+00:00 https://formycon.metamove.net/blog/press-release/formycon-erhaelt-zulassung-in-grossbritannien-fuer-fyb203-aflibercept-ein-biosimilar-zu-eylea-unter-dem-markennamen-ahzantive/ 2025-07-08T07:48:29+00:00 https://formycon.metamove.net/blog/press-release/formycon-praesentiert-klinische-daten-zu-ustekinumab-biosimilar-fyb202-auf-dem-ecco-kongress-in-berlin/ 2025-07-08T07:48:46+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-informiert-ueber-juengste-entwicklungen-in-verschiedenen-biosimilar-projekten-und-laedt-zur-telefonkonferenz-ein/ 2025-07-08T07:48:52+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-entscheidung-zu-phase-iii-studie-von-fyb206-bekannt-und-informiert-ueber-potenziellen-anpassungsbedarf-bei-der-bewertung-von-fyb202-und-fyb201/ 2025-07-08T07:48:58+00:00 https://formycon.metamove.net/blog/press-release/lotus-pharmaceutical-wird-strategischer-vermarktungspartner-fuer-formycons-eylea-biosimilar-fyb203-ahzantive-in-der-asien-pazifik-region/ 2025-07-08T07:49:04+00:00 https://formycon.metamove.net/blog/press-release/formycon-erhaelt-eu-zulassung-fuer-fyb203-aflibercept-ein-biosimilar-zu-eylea-unter-den-markennamen-ahzantive-und-baiama/ 2025-07-08T07:49:12+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-fresenius-kabi-geben-die-zulassung-von-fyb202-otulfi-ustekinumab-einem-biosimilar-zu-stelara-durch-die-britische-mhra-bekannt/ 2025-07-08T07:49:20+00:00 https://formycon.metamove.net/blog/press-release/formycon-wird-in-den-tecdax-der-deutschen-boerse-aufgenommen/ 2025-07-08T07:49:34+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-fresenius-kabi-canada-erhalten-zulassung-von-health-canada-fuer-fyb202-otulfi-ustekinumab-ein-biosimilar-zu-stelara/ 2025-07-08T07:49:40+00:00 https://formycon.metamove.net/en/blog/press-release/bio-usawa-becomes-partner-for-the-commercialization-of-fyb201-bioucenta-ranibizumab-across-sub-saharan-africa/ 2025-07-08T07:50:10+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-increases-bond-volume-following-oversubscription-bond-2025-2029-with-a-volume-of-eur-70-million-successfully-and-entirely-placed/ 2025-07-08T07:50:19+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-successfully-places-an-eur-70-million-senior-unsecured-floating-rate-bond/ 2025-07-08T07:50:26+00:00 https://formycon.metamove.net/en/blog/press-release/u-s-biosimilar-specialist-valorum-biologics-llc-becomes-commercialization-partner-for-formycons-eylea-biosimilar-fyb203-ahzantive-aflibercept-mrbb-in-the-united-states-and-cana/ 2025-07-08T07:50:40+00:00 https://formycon.metamove.net/en/blog/press-release/strong-demand-for-formycon-2025-2029-bond-leads-to-early-closing-of-subscription-period/ 2025-07-08T07:50:48+00:00 https://formycon.metamove.net/en/blog/press-release/early-end-of-the-offer-period-for-the-bond-due-to-high-demand/ 2025-07-08T07:50:55+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-bond-2025-2029-public-subscription-now-also-possible-via-deutsche-boerse/ 2025-07-08T07:51:02+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-plans-public-corporate-bond-issuance-to-support-next-growth-phase-within-attractive-biosimilar-markets/ 2025-07-08T07:51:15+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-plans-to-issue-a-public-senior-unsecured-floating-rate-bond-with-target-volume-of-eur-50-million-to-support-further-company-growth/ 2025-07-08T07:51:23+00:00 https://formycon.metamove.net/en/blog/press-release/lucentis-biosimilar-fyb201-ranivisio-ranibizumab-approved-in-brazil/ 2025-07-08T07:51:31+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-announce-the-commercial-launch-of-fyb202-otulfi-an-approved-ustekinumab-biosimilar-in-canada/ 2025-07-08T07:51:38+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-announce-fda-approval-of-interchangeability-for-fyb202-otulfi-ustekinumab-aauz/ 2025-07-08T07:51:45+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-strong-operational-performance-and-financial-results-for-first-quarter-of-2025/ 2025-07-08T07:51:52+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-conference-call-on-the-results-of-the-first-quarter-of-2025-and-announces-participation-in-international-investor-conferences/ 2025-07-08T07:51:58+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-on-a-successful-financial-year-2024-with-strong-operational-progress-and-continuous-strengthening-of-its-market-position/ 2025-07-08T07:52:05+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-conference-call-on-the-results-of-the-financial-year-2024-and-announces-participation-in-international-investor-conferences-in-the-2nd-quarter-of-2025/ 2025-07-08T07:52:12+00:00 https://formycon.metamove.net/en/blog/press-release/fyb202-otulfi-ustekinumab-aauz-a-biosimilar-to-stelara-launched-in-the-united-states-and-the-european-union/ 2025-07-08T07:52:18+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-receives-regulatory-approval-in-the-uk-for-fyb203-aflibercept-a-biosimilar-to-eylea-under-the-brand-name-ahzantive/ 2025-07-08T07:52:25+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-presents-clinical-data-on-ustekinumab-biosimilar-fyb202-at-the-ecco-congress-in-berlin/ 2025-07-08T07:52:35+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-informs-about-recent-developments-in-various-biosimilar-projects-and-invites-to-conference-call/ 2025-07-08T07:52:41+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-decision-on-phase-iii-trial-with-fyb206-and-provides-update-on-potential-need-to-adjust-the-valuation-of-fyb202-and-fyb201/ 2025-07-08T07:52:48+00:00 https://formycon.metamove.net/en/blog/press-release/lotus-pharmaceutical-becomes-strategic-partner-for-the-commercialization-of-formycons-eylea-biosimilar-fyb203-ahzantive-in-the-asia-pacific-region/ 2025-07-08T07:52:54+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-receives-eu-approval-for-fyb203-aflibercept-a-biosimilar-to-eylea-under-the-brand-names-ahzantive-and-baiama/ 2025-07-08T07:53:00+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-announce-mhra-approval-for-fyb202-otulfi-ustekinumab-a-biosimilar-to-stelara/ 2025-07-08T07:53:07+00:00 https://formycon.metamove.net/en/blog/press-release/teva-becomes-strategic-commercialization-partner-for-formycons-biosimilar-candidate-fyb203-eylea-aflibercept-in-major-parts-of-europe-and-israel/ 2025-07-08T07:53:16+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-included-in-tecdax-index-of-deutsche-borse/ 2025-07-08T07:53:22+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-fresenius-kabi-canada-receive-health-canadas-approval-for-fyb202-otulfi-ustekinumab-a-biosimilar-to-stelara/ 2025-07-08T07:53:31+00:00 https://formycon.metamove.net/blog/press-release/formycon-schliesst-patientenrekrutierung-fuer-die-klinische-entwicklung-des-keytruda-biosimilar-kandidaten-fyb206-erfolgreich-ab/ 2025-07-10T04:34:41+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-successfully-completes-patient-enrollment-for-the-clinical-development-of-its-keytruda-biosimilar-candidate-fyb206/ 2025-07-10T04:34:41+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-telefonkonferenz-zu-den-ergebnissen-des-ersten-halbjahres-2025-ein-und-gibt-teilnahme-an-internationalen-investorenkonferenzen-im-3-quartal-2025-bekannt/ 2025-07-30T04:35:06+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-conference-call-on-2025-half-year-results-and-announces-participation-in-international-investor-conferences-in-the-3rd-quarter-of-2025/ 2025-07-30T04:35:06+00:00 https://formycon.metamove.net/blog/press-release/formycon-bestaetigt-jahresprognose-nach-planmaessiger-geschaeftsentwicklung-und-hebt-working-capital-an/ 2025-08-13T04:33:11+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-confirms-full-year-guidance-following-business-development-in-line-with-plan-working-capital-raised/ 2025-08-13T04:33:11+00:00 https://formycon.metamove.net/en/blog/press-release/horus-pharma-becomes-additional-commercialization-partner-for-formycons-eylea-biosimilar-fyb203-in-selected-european-countries-under-the-brand-name-baiama/ 2025-09-17T04:34:57+00:00 https://formycon.metamove.net/blog/press-release/horus-pharma-wird-zweitvermarktungspartner-fuer-formycons-eylea-biosimilar-fyb203-unter-der-marke-baiama-in-ausgewaehlten-europaeischen-laendern/ 2025-09-17T04:34:57+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-secures-u-s-license-date-for-proposed-aflibercept-biosimilar-fyb203-following-settlement-and-license-agreement-with-regeneron/ 2025-10-02T04:37:39+00:00 https://formycon.metamove.net/blog/press-release/formycon-sichert-us-vermarktungsstart-fuer-aflibercept-biosimilar-fyb203-durch-settlement-vereinbarung-mit-regeneron/ 2025-10-02T04:44:50+00:00 https://formycon.metamove.net/blog/press-release/actor-pharmaceuticals-und-megalabs-werden-vermarktungspartner-fuer-formycons-eylea-biosimilar-fyb203-aflibercept-in-australien-und-lateinamerika/ 2025-10-16T04:34:56+00:00 https://formycon.metamove.net/en/blog/press-release/actor-pharmaceuticals-and-megalabs-become-partners-for-the-commercialization-of-formycons-eylea-biosimilar-fyb203-aflibercept-for-australia-and-latin-america/ 2025-10-16T04:34:56+00:00 https://formycon.metamove.net/blog/press-release/teva-wird-strategischer-vermarktungspartner-fuer-formycons-biosimilar-kandidat-fyb203-eylea-aflibercept-in-weiten-teilen-europas-und-israel/ 2025-10-17T10:37:16+00:00 https://formycon.metamove.net/en/blog/press-release/formycons-fyb201-ranivisio-sets-innovative-standard-as-europes-first-ranibizumab-biosimilar-available-in-pre-filled-syringe/ 2025-10-21T04:34:59+00:00 https://formycon.metamove.net/blog/press-release/formycon-setzt-neuen-standard-fyb201-ranivisio-ist-das-erste-ranibizumab-biosimilar-europas-in-einer-fertigspritze/ 2025-10-21T04:34:59+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-conference-call-on-2025-nine-month-results-and-announces-participation-in-investor-conferences-in-the-4th-quarter-of-2025/ 2025-10-30T05:34:16+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-telefonkonferenz-zum-neunmonatsergebnis-2025-ein-und-gibt-teilnahme-an-investorenkonferenzen-im-4-quartal-2025-bekannt/ 2025-10-30T05:34:16+00:00 https://formycon.metamove.net/blog/press-release/formycon-veroeffentlicht-neunmonatsergebnis-und-bestaetigt-prognose-pipeline-fortschritte-und-starke-partnerschaften-praegen-geschaeftsjahr-2025/ 2025-11-13T05:35:59+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-publishes-nine-month-results-and-confirms-guidance-pipeline-progress-and-strong-partnerships-drive-fiscal-year-2025/ 2025-11-13T05:35:59+00:00 https://formycon.metamove.net/en/blog/press-release/milestone-achieved-with-fyb208-biosimilar-candidate-for-dupixent-dupilumab-as-another-growth-driver-in-formycons-portfolio/ 2025-11-17T05:34:28+00:00 https://formycon.metamove.net/blog/press-release/meilenstein-bei-fyb208-erreicht-biosimilar-kandidat-fuer-dupixent-dupilumab-als-weiterer-wachstumstreiber-im-formycon-portfolio/ 2025-11-17T05:34:28+00:00 https://formycon.metamove.net/en/blog/press-release/ranibizumab-biosimilar-epruvy-launched-in-germany/ 2025-11-20T05:34:24+00:00 https://formycon.metamove.net/blog/press-release/ranibizumab-biosimilar-epruvy-ab-sofort-in-deutschland-verfuegbar/ 2025-11-20T05:34:24+00:00 https://formycon.metamove.net/en/blog/press-release/ntc-becomes-commercialization-partner-for-formycons-eylea-biosimilar-fyb203-baiama-in-italy/ 2025-11-24T05:34:59+00:00 https://formycon.metamove.net/blog/press-release/ntc-wird-kommerzialisierungspartner-fuer-formycons-eylea-biosimilar-fyb203-baiama-in-italien/ 2025-11-24T05:34:59+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-ms-pharma-schliessen-exklusive-kommerzialisierungspartnerschaft-fuer-den-keytruda-biosimilar-kandidaten-fyb206-in-der-mena-region/ 2025-12-04T06:44:42+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-ms-pharma-sign-exclusive-commercialization-partnership-for-keytruda-biosimilar-candidate-fyb206-for-the-mena-region/ 2025-12-04T06:44:42+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-zydus-schliessen-exklusive-lizenz-und-liefervereinbarung-fuer-fyb206-ein-biosimilar-fuer-keytruda-pembrolizumab-in-den-usa-und-kanada/ 2025-12-09T12:07:37+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-and-zydus-partner-for-exclusive-licensing-and-supply-agreement-of-fyb206-a-biosimilar-to-keytruda-pembrolizumab-in-the-u-s-and-canada/ 2025-12-09T12:07:54+00:00 https://formycon.metamove.net/en/blog/press-release/fda-approves-another-interchangeable-ranibizumab-biosimilar-nufymco-strengthening-us-presence-with-zydus-as-commercialization-partner/ 2025-12-23T12:47:48+00:00 https://formycon.metamove.net/blog/press-release/fda-erteilt-zulassung-fuer-weiteres-austauschbares-ranibizumab-biosimilar-nufymco-staerkung-der-us-praesenz-mit-zydus-als-vermarktungspartner/ 2025-12-23T13:04:30+00:00 https://formycon.metamove.net/en/blog/press-release/subscription-period-for-2025-2029-corporate-bond-has-started/ 2026-01-30T11:57:29+00:00 https://formycon.metamove.net/en/blog/press-release/ordinary-annual-general-meeting-of-formycon-ag-approves-all-proposed-resolutions-by-large-majorities/ 2026-02-10T12:42:07+00:00 https://formycon.metamove.net/en/blog/press-release/lotus-pharmaceutical-becomes-commercialization-partner-for-formycons-keytruda-biosimilar-candidate-fyb206-across-major-parts-of-the-asia-pacific-region/ 2026-02-11T07:28:13+00:00 https://formycon.metamove.net/blog/press-release/lotus-pharmaceutical-wird-vermarktungspartner-fuer-formycons-keytruda-biosimilar-kandidaten-fyb206-in-weiten-teilen-der-asien-pazifik-region/ 2026-02-11T07:28:47+00:00 https://formycon.metamove.net/blog/press-release/formycon-gibt-positive-klinische-daten-fuer-den-keytruda-biosimilar-kandidaten-fyb206-pembrolizumab-bekannt/ 2026-02-25T05:34:05+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-announces-positive-clinical-data-for-keytruda-biosimilar-candidate-fyb206-pembrolizumab/ 2026-02-25T05:34:07+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-veroeffentlicht-vorlaeufige-zahlen-fuer-das-geschaeftsjahr-2025/ 2026-03-04T22:11:06+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-publishes-preliminary-figures-for-the-2025-fiscal-year/ 2026-03-04T22:11:25+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-postpones-the-publication-of-its-audited-annual-and-consolidated-financial-statements-for-2025/ 2026-03-18T17:55:45+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-verschiebt-veroeffentlichung-ihres-testierten-jahres-und-konzernabschlusses-2025/ 2026-03-18T17:55:45+00:00 https://formycon.metamove.net/blog/press-release/formycon-sichert-vermarktungsstart-fuer-aflibercept-2-mg-biosimilar-fyb203-in-europa-und-weiteren-territorien-durch-settlement-mit-regeneron-und-bayer/ 2026-03-19T05:34:47+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-secures-license-date-for-aflibercept-2-mg-biosimilar-fyb203-in-europe-and-further-territories-following-settlement-with-regeneron-and-bayer/ 2026-03-19T05:39:02+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-informiert-ueber-verbesserte-vorlaeufige-ergebniszahlen-fuer-das-geschaeftsjahr-2025-und-gibt-datum-fuer-die-veroeffentlichung-des-jahresabschlusses-bekannt/ 2026-04-15T19:06:53+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-announces-improved-preliminary-figures-for-the-2025-fiscal-year-and-sets-date-for-the-publication-of-the-annual-financial-statements/ 2026-04-15T19:08:03+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-telefonkonferenz-zu-den-ergebnissen-des-geschaeftsjahres-2025-ein-und-gibt-teilnahme-an-internationalen-investorenkonferenzen-im-2-quartal-2026-bekannt/ 2026-04-20T04:34:42+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-conference-call-on-the-results-of-the-financial-year-2025-and-announces-participation-in-international-investor-conferences-in-the-2nd-quarter-of-2026/ 2026-04-20T04:34:54+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-erfolgreiches-geschaeftsjahr-2025-mit-wichtigen-operativen-fortschritten-wachsender-marktpraesenz-und-wegweisenden-partnerschaften/ 2026-04-22T04:34:06+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-successful-financial-year-2025-with-important-operational-progress-growing-market-presence-and-strategic-partnerships/ 2026-04-22T04:35:00+00:00 https://formycon.metamove.net/blog/press-release/formycon-erweitert-kommerzielles-portfolio-aflibercept-biosimilars-ahzantive-und-baiama-in-der-europaeischen-union-verfuegbar/ 2026-05-19T04:34:11+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-expands-commercial-portfolio-aflibercept-biosimilars-ahzantive-and-baiama-are-now-available-in-the-european-union/ 2026-05-19T04:34:23+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-telefonkonferenz-zu-den-ergebnissen-des-ersten-quartals-2026-ein-und-gibt-teilnahme-an-internationalen-investorenkonferenzen-bekannt/ 2026-05-21T04:34:29+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-conference-call-on-the-results-of-the-first-quarter-of-2026-and-announces-participation-in-international-investor-conferences/ 2026-05-21T04:34:41+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-positive-operative-fortschritte-und-stark-wachsende-umsaetze-im-ersten-quartal-2026/ 2026-05-28T04:34:22+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-positive-operational-progress-and-strong-revenue-growth-in-the-first-quarter-of-2026/ 2026-05-28T04:39:27+00:00 https://formycon.metamove.net/blog/press-release/formycon-ag-informiert-ueber-die-ergebnisse-der-ordentlichen-hauptversammlung/ 2026-06-10T14:22:45+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-reports-results-of-annual-general-meeting-2026/ 2026-06-10T14:23:03+00:00 https://formycon.metamove.net/blog/press-release/formycon-und-onesource-specialty-pharma-geben-strategische-partnerschaft-fuer-die-herstellung-von-biosimilars-bekannt/ 2026-07-14T05:04:18+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-ag-and-onesource-specialty-pharma-announce-strategic-manufacturing-partnership-for-biosimilars/ 2026-07-14T05:05:34+00:00 https://formycon.metamove.net/blog/press-release/formycon-laedt-zur-telefonkonferenz-zu-den-ergebnissen-des-ersten-halbjahres-2026-ein-und-gibt-teilnahme-an-internationalen-investorenkonferenzen-bekannt/ 2026-08-05T04:35:31+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-invites-to-conference-call-on-2026-half-year-results-and-announces-participation-in-international-investor-conferences/ 2026-08-05T04:35:31+00:00 https://formycon.metamove.net/en/blog/press-release/formycon-reports-key-operational-achievements-in-the-first-half-of-2026-and-significantly-improves-financial-results-year-on-year/ 2026-08-12T04:34:09+00:00 https://formycon.metamove.net/blog/press-release/formycon-berichtet-ueber-wichtige-operative-erfolge-im-ersten-halbjahr-2026-und-zeigt-deutlich-verbesserte-finanzzahlen-im-vergleich-zum-vorjahreszeitraum/ 2026-08-12T04:34:09+00:00